Back to Search
Start Over
Facilitating return of actionable genetic research results from a biobank repository: Participant uptake and utilization of digital interventions.
- Source :
-
HGG advances [HGG Adv] 2024 Aug 24; Vol. 5 (4), pp. 100346. Date of Electronic Publication: 2024 Aug 24. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Research participants report interest in receiving genetic research results. How best to return results remains unclear. In this randomized pilot study, we sought to assess the feasibility of returning actionable research results through a two-step process including a patient-centered digital intervention as compared with a genetic counselor (GC) in the Penn Medicine biobank. In Step 1, participants with an actionable result and procedural controls (no actionable result) were invited to digital pre-disclosure education and provided options for opting out of results. In Step 2, those with actionable results who had not opted out were randomized to receive results via a digital disclosure intervention or with a GC. Five participants (2%) opted out of results after Step 1. After both steps, 52 of 113 (46.0%) eligible cases received results, 5 (4.4%) actively declined results, 34 (30.1%) passively declined, and 22 (19.5%) could not be reached. Receiving results was associated with younger age (p < 0.001), completing pre-disclosure education (p < 0.001), and being in the GC arm (p = 0.06). Being older, female, and of Black race were associated with being unable to reach. Older age and Black race were associated with passively declining. Forty-seven percent of those who received results did not have personal or family history to suggest the mutation, and 55.1% completed clinical confirmation testing. The use of digital tools may be acceptable to participants and could reduce costs of returning results. Low uptake, disparities in uptake, and barriers to confirmation testing will be important to address to realize the benefit of returning actionable research results.<br />Competing Interests: Declaration of interests A.R.B. receives partial research funding from AstraZeneca and Merck for other studies.<br /> (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2666-2477
- Volume :
- 5
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- HGG advances
- Publication Type :
- Academic Journal
- Accession number :
- 39183478
- Full Text :
- https://doi.org/10.1016/j.xhgg.2024.100346